Esperion Therapeutics
Market Cap
US$1.4b
Last Updated
2019/12/13 00:50 UTC
Data Sources
Company Financials +
Executive Summary
Esperion Therapeutics, Inc., a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C).
Rewards
Risk Analysis
Earnings are forecast to decline by an average of -6.1% per year for the next 3 years
Currently unprofitable and not forecast to become profitable over the next 3 years
Snowflake Analysis
Flawless balance sheet with concerning outlook.
Share Price & News
How has Esperion Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ESPR's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
2.8%
ESPR
0.8%
US Biotechs
1.3%
US Market
1 Year Return
7.0%
ESPR
16.4%
US Biotechs
19.4%
US Market
Return vs Industry: ESPR underperformed the US Biotechs industry which returned 16.4% over the past year.
Return vs Market: ESPR underperformed the US Market which returned 19.4% over the past year.
Shareholder returns
| ESPR | Industry | Market | |
|---|---|---|---|
| 7 Day | 2.8% | 0.8% | 1.3% |
| 30 Day | 26.6% | 8.9% | 2.6% |
| 90 Day | 40.5% | 16.0% | 5.0% |
| 1 Year | 7.0%7.0% | 17.4%16.4% | 22.0%19.4% |
| 3 Year | 295.3%295.3% | 27.2%23.0% | 46.8%37.3% |
| 5 Year | 34.1%34.1% | 4.6%-0.5% | 66.3%48.0% |
Price Volatility Vs. Market
How volatile is Esperion Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall St
Announcing: Esperion Therapeutics (NASDAQ:ESPR) Stock Soared An Exciting 332% In The Last Three Years1 month ago | Simply Wall St
How Much Are Esperion Therapeutics, Inc. (NASDAQ:ESPR) Insiders Spending On Buying Shares?2 months ago | Simply Wall St
We Think Esperion Therapeutics (NASDAQ:ESPR) Can Easily Afford To Drive Business GrowthValuation
Is Esperion Therapeutics undervalued compared to its fair value and its price relative to the market?
20.37x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate ESPR's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate ESPR's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: ESPR is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: ESPR is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ESPR's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ESPR is overvalued based on its PB Ratio (20.4x) compared to the US Biotechs industry average (3.3x).
Next Steps
Future Growth
How is Esperion Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?
-6.1%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ESPR is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ESPR is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ESPR is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ESPR's revenue (18.1% per year) is forecast to grow faster than the US market (7.3% per year).
High Growth Revenue: ESPR's revenue (18.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ESPR's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has Esperion Therapeutics performed over the past 5 years?
-25.9%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ESPR is currently unprofitable.
Growing Profit Margin: ESPR is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ESPR is unprofitable, and losses have increased over the past 5 years at a rate of -25.9% per year.
Accelerating Growth: Unable to compare ESPR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ESPR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (103.3%).
Return on Equity
High ROE: ESPR has a negative Return on Equity (-139.04%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Next Steps
Financial Health
How is Esperion Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: ESPR's short term assets ($253.5M) exceed its short term liabilities ($57.5M).
Long Term Liabilities: ESPR's short term assets ($253.5M) exceed its long term liabilities ($129.2M).
Debt to Equity History and Analysis
Debt Level: ESPR is debt free.
Reducing Debt: ESPR has no debt compared to 5 years ago when its debt to equity ratio was 9.6%.
Balance Sheet
Inventory Level: ESPR has a low level of unsold assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if ESPR's debt is covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ESPR has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: ESPR has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of -0.3% each year
Next Steps
Dividend
What is Esperion Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate ESPR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate ESPR's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ESPR's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ESPR's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ESPR's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
What is the CEO of Esperion Therapeutics's salary, the management and board of directors tenure and is there insider trading?
1.7yrs
Average management tenure
CEO
Tim Mayleben (58yo)
7yrs
Tenure
US$9,724,839
Compensation
Mr. Timothy M. Mayleben, also known as Tim, M.B.A., has been the Chief Executive Officer and President of Esperion Therapeutics, Inc. since December 2012. Mr. Mayleben serves as an Advisor to several biote ...
CEO Compensation Analysis
Compensation vs Market: Tim's total compensation ($USD9.72M) is above average for companies of similar size in the US market ($USD3.89M).
Compensation vs Earnings: Tim's compensation has increased whilst the company is unprofitable.
Management Age and Tenure
1.7yrs
Average Tenure
53yo
Average Age
Experienced Management: ESPR's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.
Board Age and Tenure
4.5yrs
Average Tenure
58yo
Average Age
Experienced Board: ESPR's board of directors are considered experienced (4.5 years average tenure).
Insider Trading
Insider Buying: ESPR insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
| Entity | Individual |
| Role | Chief Executive Officer President |
| Shares | 5,000 |
| Max Price | US$36.98 |
| Entity | Company |
| Shares | 75,000 |
| Max Price | US$37.30 |
| Entity | Individual |
| Role | Chief Executive Officer President |
| Shares | 7,500 |
| Max Price | US$35.25 |
| Entity | Company |
| Shares | 80,000 |
| Max Price | US$33.78 |
| Entity | Individual |
| Role | Chief Executive Officer President |
| Shares | 5,000 |
| Max Price | US$39.56 |
| Entity | Company |
| Shares | 50,000 |
| Max Price | US$42.65 |
| Entity | Individual |
| Role | Chief Executive Officer President |
| Shares | 5,000 |
| Max Price | US$46.00 |
| Entity | Individual |
| Role | Chief Executive Officer President |
| Shares | 5,000 |
| Max Price | US$40.00 |
| Entity | Individual |
| Role | Chief Executive Officer President |
| Shares | 5,000 |
| Max Price | US$43.48 |
| Entity | Company |
| Shares | 1,700 |
| Max Price | US$45.25 |
| Entity | Company |
| Shares | 13,629 |
| Max Price | US$44.66 |
| Entity | Company |
| Shares | 50,000 |
| Max Price | US$49.89 |
| Entity | Individual |
| Role | Chief Executive Officer President |
| Shares | 5,000 |
| Max Price | US$48.73 |
| Entity | Company |
| Shares | 80,000 |
| Max Price | US$41.29 |
| Entity | Company |
| Shares | 50,000 |
| Max Price | US$39.91 |
| Entity | Company |
| Shares | 60,000 |
| Max Price | US$47.73 |
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Management Team
Tim Mayleben (58yo)
President
- Tenure: 7yrs
- Compensation: US$9.72m
Ken Fiorelli
Senior Vice President of Technical Operations
- Tenure: 0.3yrs
Keith Lenden (46yo)
Vice President of Corporate Development & Strategy
- Tenure: 0yrs
Bill Sasiela (53yo)
Senior Vice President of Clinical Development
- Tenure: 1.7yrs
Mark Glickman (53yo)
Chief Commercial Officer
- Tenure: 1.7yrs
- Compensation: US$9.12m
Regina Cavaliere
Chief Ethics & Compliance Officer
- Tenure: 0.4yrs
Rick Bartram (37yo)
CFO & Corporate Secretary
- Tenure: 1.9yrs
- Compensation: US$2.54m
Ashley Hall
Chief Development Officer
- Tenure: 1.7yrs
Alex Schwartz
Senior Director of Investor Relations
- Tenure: 1.6yrs
Renee Marotta
Head of Marketing
- Tenure: 0yrs
Board Members
Dan Janney (54yo)
Independent Director
- Tenure: 7.1yrs
- Compensation: US$270.58k
Nicole Vitullo (62yo)
Lead Independent Director
- Tenure: 4yrs
- Compensation: US$311.66k
Tim Mayleben (58yo)
President
- Tenure: 7yrs
- Compensation: US$9.72m
Antonio Gotto (84yo)
Independent Director
- Tenure: 5.9yrs
- Compensation: US$290.84k
Jay Shepard (61yo)
Independent Director
- Tenure: 1.6yrs
- Compensation: US$477.34k
Jeff Berkowitz (53yo)
Director
- Tenure: 2yrs
- Compensation: US$1.41m
Tracy Woody (49yo)
Director
- Tenure: 0.6yrs
Scott Braunstein (56yo)
Independent Director
- Tenure: 4.5yrs
- Compensation: US$305.63k
Mark McGovern (66yo)
Independent Director
- Tenure: 5.8yrs
- Compensation: US$287.35k
Company Information
Esperion Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Esperion Therapeutics, Inc.
- Ticker: ESPR
- Exchange: NasdaqGM
- Founded: 2008
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$1.403b
- Shares outstanding: 27.33m
- Website: https://www.esperion.com
Number of Employees
Location
- Esperion Therapeutics, Inc.
- 3891 Ranchero Drive
- Suite 150
- Ann Arbor
- Michigan
- 48108
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| ESPR | NasdaqGM (Nasdaq Global Market) | Yes | Common Stock | US | USD | Jun 2013 |
| 0ET | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Jun 2013 |
| 0IIM | LSE (London Stock Exchange) | Yes | Common Stock | GB | USD | Jun 2013 |
Biography
Esperion Therapeutics, Inc., a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). It ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/12/13 00:50 |
| End of Day Share Price | 2019/12/12 00:00 |
| Earnings | 2019/09/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.